Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
